Penumbra (PEN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Penumbra

NYSE•Healthcare•Medical Devices

$324.39-0.57(<0.01%)Pre-market

Market Cap

$12.61B

P/E

80.3x

P/S

8.1x

P/B

8.0x

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

How this company scores

GoodMetricSide Score: 68/100

Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (13/25).

Profitability13/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality23/25

Strengths

Growing revenueRising free cash flowInterest easily coveredConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 80.3x5y range 60.0x – 2031.1x

Currently below its 16-quarter median.

P/S · 8.1x5y range 6.1x – 14.4x

Currently near its 20-quarter median.

P/B · 8.0x5y range 5.1x – 12.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 6.4% — watch for continued compression, which may signal competitive or cost pressure.

Share Dilution

Watch

Shares outstanding rose 2.6% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $12.61B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.56B
Q. Revenue: $410.14M
TTM EBITDA: $209.36M
TTM Op. Income: $189.25M
Q. Op. Income: $50.74M
TTM Net Income: $157.02M
Q. Net Income: $42.28M
EPS: $1.07
Shares Out.: $39.40M

$1.56B in TTM revenue grew 17.0% YoY, reaching $410.14M last quarter. TTM EBITDA of $209.36M and TTM operating income of $189.25M show growth is flowing through to the bottom line. TTM net income of $157.02M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 68.3%
EBITDA Margin: 13.7%
Op. Margin: 12.4%
Net Margin: 10.3%

Op. margin of 12.4% is down 1.4% YoY — costs are rising relative to revenue. Net margin at 10.3% and gross margin of 68.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 80.3x
P/S Ratio: 8.1x
P/B Ratio: 8.0x

At 80.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 8.1x and P/B of 8.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.03B
Cash: $254.28M
Long-Term Debt: N/A
Book Value: $1.58B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $41.51M
TTM Free Cash Flow: $200.29M
FCF Margin: 12.8%
FCF / Net Income: 1.3

TTM FCF of $200.29M on $41.51M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 31% — a weakening trend.